Cancer stem cells are a small subpopulation of cells within a tumor that can renew themselves indefinitely and generate all the other cell types found in that tumor. They often make up less than 1% of the total cancer cell population, but they play an outsized role in driving tumor growth, resisting treatment, and fueling recurrence after therapy appears to have worked.
Understanding these cells helps explain one of the most frustrating patterns in cancer treatment: a tumor that shrinks dramatically with chemotherapy, only to come back months or years later.
How Cancer Stem Cells Differ From Normal Stem Cells
Your body relies on normal stem cells to maintain and repair tissues. These cells can copy themselves (self-renewal) and mature into specialized cell types (differentiation). Tightly regulated signaling pathways keep this process in check, ensuring the right number of new cells are produced at the right time.
Cancer stem cells hijack these same self-renewal mechanisms, but the controls are broken. The pathways that normally limit how often a stem cell divides become overactive or lose their braking signals. The result is uncontrolled proliferation. Where a normal stem cell produces just enough daughter cells to replace worn-out tissue, a cancer stem cell keeps dividing and generating new tumor cells with no off switch.
Three signaling pathways are especially important in this process: Notch, Wnt, and Hedgehog. In healthy tissue, these pathways guide embryonic development and tissue maintenance. In cancer stem cells, persistent abnormal activation of one or more of these pathways delays differentiation, maintains the ability to divide, and promotes survival. These pathways also talk to each other. Blocking one can sometimes dampen the activity of another, which makes them attractive targets for future treatments.
Where Cancer Stem Cells Come From
Scientists have proposed two broad models for how tumors develop, and cancer stem cells sit at the center of the debate.
The hierarchy model says tumors are organized like a pyramid. A small number of cancer stem cells sit at the top and give rise to all the different cell types within the tumor, much like normal stem cells generate the various specialized cells in an organ. In this view, not every cancer cell is equally dangerous. Only the stem cells at the top can sustain the tumor long-term.
The stochastic model takes the opposite view: any cancer cell could potentially acquire the ability to drive tumor growth through random mutations. There is no fixed hierarchy, just probability.
Growing evidence suggests the reality is more complicated than either model alone. Researchers have shown that when certain non-stem cancer cells undergo a process called epithelial-to-mesenchymal transition, a shape-shifting change where cells become more mobile and invasive, they can acquire stem cell properties. This means the cancer stem cell population is not necessarily fixed. Ordinary tumor cells can, under certain conditions, convert into stem-like cells. That finding, first demonstrated in breast cancer cells, revealed that the stem cell state can be generated on the fly, creating a self-renewing population that persists even after the triggering signal is gone.
Why They Survive Chemotherapy
Standard chemotherapy and radiation target cells that are actively dividing. That works well against the bulk of a tumor, where cells are rapidly multiplying. Cancer stem cells dodge this approach in several ways.
First, many cancer stem cells sit in a dormant, non-dividing state called quiescence. They are essentially idling in a resting phase of the cell cycle, invisible to treatments designed to hit rapidly growing cells. When therapy ends, these dormant cells can reawaken and rebuild the tumor, giving rise to what clinicians call “second-line tumors” that often carry new resistance.
Second, cancer stem cells carry high levels of drug efflux pumps on their surface. These are molecular transporters that actively push chemotherapy drugs back out of the cell before they can do damage. One well-known transporter, ABCG2, is a hallmark of cancer stem cells across many tumor types.
Third, cancer stem cells have unusually efficient DNA repair machinery. When chemotherapy or radiation does manage to damage their DNA, these cells can patch themselves up more effectively than ordinary tumor cells. They also use altered metabolic pathways and produce enzymes that neutralize certain drugs. One such enzyme, ALDH1A1, breaks down toxic compounds and is found at elevated levels in the stem cell fraction of breast and other cancers.
The Protective Niche
Cancer stem cells do not survive alone. They are sheltered by a specialized local environment, or niche, within the tumor. This niche includes surrounding support cells, immune cells, and physical structures that work together to keep stem cells safe.
Low-oxygen zones (hypoxia) within the tumor are particularly important. Hypoxia slows down the cell cycle of cancer stem cells, which protects their DNA from damage and further shields them from chemotherapy and radiation. Hypoxic conditions also promote the epithelial-to-mesenchymal transition that generates new stem-like cells.
The niche actively suppresses the immune system’s ability to find and destroy cancer stem cells. Certain immune cells within the tumor, including regulatory T cells and tumor-associated macrophages, dampen the killing power of the body’s natural cancer fighters. This creates a local zone of immune suppression around the stem cells.
Even the physical structure of the tumor plays a role. Stiffened tissue surrounding the niche can act as a physical barrier, blocking therapeutic drugs from reaching the stem cells. When cancer stem cells break free and enter the bloodstream, they can surround themselves with platelets, forming a physical shield against immune attack and the shear forces of blood flow.
How Researchers Identify Them
Cancer stem cells are identified primarily by proteins on their surface and enzymes inside the cell. No single marker works for every cancer type, but a few show up repeatedly across different tumors.
- CD44 is one of the most widely used markers, particularly in breast cancer. It is found on the surface of stem-like cells and plays roles in cell adhesion and migration.
- CD133 was first identified as a cancer stem cell marker in colorectal cancer and has since been linked to stem cells in glioblastoma, liver cancer, and other solid tumors. In glioblastoma, CD133 activates signaling that drives tumor growth.
- ALDH1A1 is an intracellular enzyme. Cells with high ALDH activity in breast tissue are considered stem-like and can form the spherical cell clusters characteristic of stem cell behavior in lab assays.
- ABCG2, the drug efflux transporter, doubles as both a functional resistance mechanism and a marker for identifying stem cells.
Importantly, researchers have found that using a single marker can miss entire subpopulations. In breast cancer, for instance, quiescent stem cells express mainly pluripotency markers, while a separate progenitor-like population expresses ALDH1A1 and ABCG2 but not the same pluripotency signals. That progenitor-like group is highly relevant to drug resistance and metastasis, yet a screening strategy relying on just one marker would overlook it entirely.
What This Means for Prognosis
A systematic review of 234 survival analyses found that in 82% of cases, high expression of cancer stem cell markers was linked to worse overall survival and shorter disease-free survival. This association held across a wide range of cancers: breast, gastric, ovarian, colorectal, liver, glioblastoma, pancreatic, lung (both small cell and non-small cell), bladder, prostate, head and neck, esophageal, thyroid, kidney, and cervical cancers.
Beyond survival, elevated stem cell markers were also associated with less differentiated tumors, more advanced staging, vascular invasion, deeper tumor penetration, lymph node involvement, and distant metastasis. In practical terms, a tumor with a larger or more active cancer stem cell population tends to behave more aggressively.
Despite these strong associations, no standardized clinical test exists yet for measuring cancer stem cell levels in a patient’s tumor. One approach in advanced clinical trials, the ChemoID assay, takes a patient’s own biopsy tissue and tests both bulk tumor cells and cancer stem cells against available chemotherapy drugs. The goal is to predict which treatment will work best for that individual. It is currently in phase III trials for recurrent ovarian cancer and glioblastoma, but routine clinical use remains limited.
Why Targeting Them Is So Difficult
The challenge with cancer stem cells is that they share so many features with the normal stem cells your body depends on. The same signaling pathways that keep cancer stem cells alive also maintain healthy tissues like the gut lining, blood cell production, and skin. Blocking those pathways aggressively enough to kill cancer stem cells risks serious side effects in healthy organs.
Their rarity within tumors adds another layer of difficulty. Designing a drug that can find and destroy a population making up less than 1% of the tumor, while that population is sheltered in a protected niche, dormant, and actively pumping out drugs, is a formidable problem. The ability of non-stem cancer cells to convert into stem-like cells through processes like epithelial-to-mesenchymal transition means that even eliminating the existing stem cell pool might not be enough if new ones can be generated from the remaining tumor.
Most researchers now view effective cancer treatment as requiring a two-pronged strategy: conventional therapy to shrink the bulk of the tumor, combined with targeted approaches to eliminate the stem cell population that drives regrowth. Getting both pieces right, and timing them correctly, remains one of the central challenges in oncology.